1. Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
- Author
-
Chao Zhao, Jinpeng Shi, Hui Yang, Xuefei Li, Sha Zhao, Tao Jiang, Limin Zhang, Xiaozhen Liu, Lei Xi, Shijia Zhang, Chunxia Su, Shengxiang Ren, Yan Wang, Caicun Zhou, and Yijun Jia
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,03 medical and health sciences ,Egfr tki ,0302 clinical medicine ,Internal medicine ,medicine ,Epidermal growth factor receptor ,Lung cancer ,Chemotherapy ,biology ,business.industry ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,Egfr mutation ,030220 oncology & carcinogenesis ,Cohort ,biology.protein ,Adenocarcinoma ,Original Article ,business ,Tyrosine kinase - Abstract
Objective Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon EGFR mutations remain insufficient. This study aimed to investigate the effect of first-line EGFR-TKIs or platinum-based chemotherapy in NSCLC patients with uncommon EGFR mutations. Methods We retrospectively enrolled 504 patients with EGFR-mutant NSCLC. The clinical characteristics and treatment outcomes were collected and compared between patients with common and uncommon EGFR-mutant NSCLC. Results Seventy patients (13.9%) harboring uncommon EGFR mutations were included. Thirty of these patients received EGFR-TKIs and 40 received platinum-based chemotherapy as first-line therapy. The objective response rate (ORR) and median progression-free survival (mPFS) of patients treated with TKIs in the uncommon mutation group was significantly inferior to that in the common mutation group (ORR: 23.3% vs. 51.8%, P=0.003; mPFS: 7.1 vs. 10.9 months, P
- Published
- 2017
- Full Text
- View/download PDF